Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 6:24 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 42 matching trials from the live ClinicalTrials.gov search.
Conditions
Systemic Lupus Erythematosus
Interventions
Baricitinib, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
27
States / cities
Tucson, Arizona • Beverly Hills, California • Covina, California + 22 more
Conditions
Post-Acute COVID-19 Syndrome
Interventions
Baricitinib 4 MG, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
6
States / cities
San Francisco, California • New Haven, Connecticut • Atlanta, Georgia + 2 more
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Pharmacokinetic Study of Baricitinib in Participants With Liver Disease

NCT01870388
Conditions
Liver Diseases, Hepatic Insufficiency
Interventions
Baricitinib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Conditions
COVID-19
Interventions
Baricitinib, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,525 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
25
States / cities
Gilbert, Arizona • Phoenix, Arizona • Newport Beach, California + 20 more
Conditions
Amyotrophic Lateral Sclerosis, Alzheimer Disease, Mild Cognitive Impairment
Interventions
Baricitinib
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 90 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Boston, Massachusetts • Charlestown, Massachusetts
Conditions
Rheumatoid Arthritis
Interventions
Baricitinib, TNF Inhibitor
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,050 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
119
States / cities
Chandler, Arizona • Mesa, Arizona • Paradise Valley, Arizona + 104 more
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY3009104(Baricitinib) for Healthy Subjects

NCT01247350
Conditions
Healthy Volunteer
Interventions
LY3009104, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
20 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Honolulu, Hawaii
Conditions
Rheumatoid Arthritis
Interventions
Placebo, Baricitinib, cDMARD
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
684 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
48
States / cities
Glendale, Arizona • Peoria, Arizona • Phoenix, Arizona + 45 more
Conditions
Psoriasis, Skin Diseases, Skin Diseases, Papulosquamous
Interventions
Placebo, Baricitinib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
18
States / cities
Bakersfield, California • Santa Monica, California • Miami, Florida + 15 more
Conditions
Arthritis, Rheumatoid
Interventions
LY3009104, Placebo, Methotrexate
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
31
States / cities
Paradise Valley, Arizona • Peoria, Arizona • Covina, California + 28 more
Conditions
Covid19, Corona Virus Infection
Interventions
Baricitinib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
1 Year to 18 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
Orlando, Florida • Detroit, Michigan • Cleveland, Ohio
Conditions
Human Immunodeficiency Virus
Interventions
Baricitinib 2 MG Oral Tablet, Placebo
Drug
Lead sponsor
William Tyor
Other
Eligibility
18 Years to 65 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
2
States / cities
Atlanta, Georgia
Completed Phase 4 Interventional Results available

Myositis Interstitial Lung Disease Nintedanib Trial

NCT05799755
Conditions
Myositis Associated Interstitial Lund Disease (MA-ILD)
Interventions
Nintedanib, Placebo, Standard of Care
Drug
Lead sponsor
Rohit Aggarwal, MD
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
10
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Denver, Colorado + 6 more
Conditions
Systemic Lupus Erythematosus
Interventions
Baricitinib, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
778 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
39
States / cities
Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 33 more
Conditions
Rheumatoid Arthritis
Interventions
Baricitinib, Methotrexate, Baricitinib Placebo, MTX Placebo, Folic Acid
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
588 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
47
States / cities
Glendale, Arizona • Mesa, Arizona • Peoria, Arizona + 44 more
Recruiting Phase 2 Interventional

JAK Signaling in Depression

NCT07003997
Conditions
Major Depressive Disorder
Interventions
Baricitinib, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
25 Years to 55 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Pyoderma Gangrenosum, Skin Diseases, Wound Heal, Pyoderma, Skin Ulcer
Interventions
Baricitinib
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 99 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Completed Phase 3 Interventional Results available

Adaptive COVID-19 Treatment Trial 2 (ACTT-2)

NCT04401579
Conditions
COVID-19
Interventions
Placebo, Remdesivir, Baricitinib
Other · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
1,033 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
53
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 44 more
Conditions
Frontal Fibrosing Alopecia
Interventions
Baricitinib 4 MG Oral Tablet
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
Rheumatoid Arthritis
Interventions
INCB028050, Placebo
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
41
States / cities
Birmingham, Alabama • Paradise Valley, Arizona • Peoria, Arizona + 38 more
Conditions
Graft-versus-host-disease, Graft Vs Host Disease
Interventions
Baricitinib
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Completed Phase 3 Interventional Results available

A Study in Moderate to Severe Rheumatoid Arthritis

NCT01710358
Conditions
Rheumatoid Arthritis
Interventions
Adalimumab, Baricitinib, Methotrexate, Adalimumab Placebo, Baricitinib Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
45
States / cities
Glendale, Arizona • Peoria, Arizona • Phoenix, Arizona + 39 more
Not yet recruiting Phase 2 Interventional Accepts healthy volunteers

Baricitinib Curative Repression of HIV-1

NCT07209267
Conditions
HIV Infection, HIV
Interventions
Antiretroviral Therapy (ART), Baricitinib (LY3009104) 2 mg, Baricitinib (LY3009104) 4 mg
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 70 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
2
States / cities
Atlanta, Georgia
Conditions
Cutaneous Lichen Planus
Interventions
Baricitinib (LY3009104) 2 mg, Baricitinib (LY3009104) 4 mg
Drug
Lead sponsor
Aaron R. Mangold
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Scottsdale, Arizona